论文部分内容阅读
大脑中动脉高密度标记 (ＨＭＣＡＳ)是大脑中动脉内血栓的标志。本文探讨了ＨＭＣＡＳ的临床预后及其接受静脉内组织纤溶酶原激活剂(ｒｔＰＡ)治疗的效果。方法 62 0例中～重度大脑半球急性缺血性卒中病人于症状发作后 6小时内接受静脉ｒｔＰＡ( 1 1ｍｇ/ｋｇ,静注 )或安慰?
Middle cerebral artery high density labeling (HMCAS) is a marker of middle cerebral artery thrombosis. This article explored the clinical outcome of HMCAS and its effect on treatment with intravenous tissue plasminogen activator (rtPA). Methods Sixty-two patients with severe acute hemispheric acute ischemic stroke underwent intravenous rtPA (11 mg / kg, intravenous) or placebo within 6 hours after the onset of symptoms.